Dr. Lal PathLabs Limited submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding the completion of a stake subscription transaction.
The disclosure confirms that Dr. Lal Ventures Private Limited, a wholly owned subsidiary of Dr. Lal PathLabs Limited, has completed the subscription of a 30% stake in Neuome Technologies Private Limited on August 27, 2026. This transaction was executed as per the terms and conditions of the Agreement.
As a result of this subscription completion, Neuome Technologies Private Limited has now become an associate company of Dr. Lal PathLabs Limited.
The disclosure references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended. The company notes that all required disclosures were previously made in an earlier intimation dated July 24, 2026, when the Board of Dr. Lal Ventures Private Limited initially approved this stake subscription.
The document was digitally signed by Vinay Gujral, Company Secretary & Compliance Officer of Dr. Lal PathLabs Limited, on August 27, 2026 at 18:41:33.
#DrLalPathLabs #SEBIDisclosure #Regulation30 #M&A #Neutral